Published Technical Disclosure Archive

Enhanced Bladder Cancer Treatment via Engineered Antigen Presenting Cells and BCG-Based Therapies

Publication ID: 24-11857612_0005_PTD
Published: October 28, 2025
Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Enhanced Bladder Cancer Treatment via Engineered Antigen Presenting Cells and BCG-Based Therapies,” Published Technical Disclosure No. 24-11857612_0005_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857612_0005_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,612.

Summary of the Inventive Concept

This invention envisions a next-generation bladder cancer treatment system that combines the immunotherapeutic potential of Bacillus Calmette-Guerin (BCG) with engineered antigen presenting cells, enhancing the immune response to bladder cancer cells.

Background and Problem Solved

The original patent disclosed the use of BCG and antigen presenting cells for bladder cancer treatment, but it had limitations in terms of efficacy and targeting specificity. This new inventive concept addresses these limitations by introducing engineered antigen presenting cells that selectively target bladder cancer cells, thereby enhancing the immune response and improving treatment outcomes.

Detailed Description of the Inventive Concept

The inventive concept comprises a system for treating bladder cancer, which includes a BCG-based therapeutic composition and an antigen presenting cell-based vaccine. The antigen presenting cells are engineered to selectively target bladder cancer cells and are administered in conjunction with the BCG-based therapeutic composition to enhance the immune response to bladder cancer cells. The system may also include a sensor for detecting the presence of antigen presenting cells in a subject's urine, allowing for real-time monitoring and treatment optimization.

Novelty and Inventive Step

The new claims introduce the concept of engineered antigen presenting cells that selectively target bladder cancer cells, which is a significant departure from the original patent. This inventive step enables a more targeted and effective immune response, making the treatment more efficient and reducing potential side effects.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept may include the use of different types of antigen presenting cells, such as dendritic cells or macrophages, or the incorporation of additional immunotherapeutic agents, such as checkpoint inhibitors. Variations may also include the use of different routes of administration, such as intravesical or systemic delivery.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the treatment of bladder cancer, which is a major unmet medical need. The market for bladder cancer treatments is expected to grow significantly in the coming years, and this inventive concept is well-positioned to capitalize on this trend.

CPC Classifications

SectionClassGroup
A A61 A61K39/04
A A61 A61K35/15
A A61 A61K39/00114
A A61 A61K39/001119
A A61 A61K39/39
A A61 A61K2039/515
A A61 A61K2039/585

Field of Art

Immunotherapy and cancer treatment, specifically bladder cancer immunotherapeutic approaches involving antigen presenting cells (APCs), with expertise in cellular engineering, immunological techniques, and cancer treatment methodologies

Person of Ordinary Skill (PHOSITA) Profile

A biomedical researcher or immunologist with advanced training in cancer immunotherapy, skilled in cell manipulation, understanding of immune system interactions, and experienced in developing targeted therapeutic approaches for oncological treatments

Obviousness Rationale

A person having ordinary skill would recognize that engineering antigen presenting cells to selectively target bladder cancer represents a predictable extension of the source patent's foundational work on BCG-based immunotherapies. The PTD's proposed modifications involve standard immunological engineering techniques that would be apparent to a skilled practitioner seeking to enhance the specificity and efficacy of existing BCG-based bladder cancer treatments. The combination of known immunotherapeutic components with targeted cellular engineering represents an incremental but logical advancement in the field.

Obvious Combinations & Variations

Source Patent Element
Antigen presenting cells isolated from urine or bladder mucosa of immunotherapeutic treated subjects
PTD Variation
Engineered antigen presenting cells selectively targeting bladder cancer cells
Obviousness Reasoning
Predictable modification using standard cellular engineering techniques to enhance targeting specificity, representing a routine optimization of existing cellular therapy approaches
Source Patent Element
BCG-based immunotherapeutic composition for bladder cancer treatment
PTD Variation
Combining BCG therapeutic composition with engineered antigen presenting cell vaccine
Obviousness Reasoning
Obvious combination of known immunotherapeutic components to potentially enhance treatment efficacy, utilizing standard immunological co-administration strategies
Source Patent Element
IL-15:IL-15Rα fusion protein complex for immune modulation
PTD Variation
Incorporating additional immunomodulatory agents like checkpoint inhibitors
Obviousness Reasoning
Routine exploration of complementary immunotherapeutic agents to enhance immune response, representing a standard approach in developing multi-modal cancer treatments
Source Patent Element
Antigen presenting cells derived from subjects with neoplastic diseases
PTD Variation
Adding a sensor for detecting and monitoring antigen presenting cells in urine
Obviousness Reasoning
Predictable technological enhancement using standard monitoring techniques to improve treatment tracking and personalization
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857612 and the disclosed technical variations, a person having ordinary skill in the art would find the proposed bladder cancer treatment system and methods obvious and anticipated. The incremental modifications represent predictable extensions of existing immunotherapeutic approaches, utilizing standard cellular engineering and immunological techniques to enhance BCG-based bladder cancer treatments. Consequently, any patent claims substantially similar to the disclosed variations would be rendered obvious and unpatentable under 35 U.S.C. Section 103.

Original Patent Information

Patent NumberUS 11,857,612
TitleBacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer
Assignee(s)NantCell, Inc.